XNASSMTI
Market cap283mUSD
Jan 07, Last price
32.42USD
1D
-4.11%
1Q
1.06%
Jan 2017
755.41%
Name
Sanara Medtech Inc
Chart & Performance
Profile
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 64,990 41.77% | 45,843 89.87% | |||||||
Cost of revenue | 11,985 | 55,704 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 53,005 | (9,861) | |||||||
NOPBT Margin | 81.56% | ||||||||
Operating Taxes | (5,845) | ||||||||
Tax Rate | |||||||||
NOPAT | 53,005 | (4,017) | |||||||
Net income | (4,303) -46.82% | (8,092) 10.77% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 911 | ||||||||
BB yield | -0.27% | ||||||||
Debt | |||||||||
Debt current | 1,303 | 314 | |||||||
Long-term debt | 12,949 | 1,325 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 4,665 | 6,004 | |||||||
Net debt | 6,020 | (10,405) | |||||||
Cash flow | |||||||||
Cash from operating activities | (3,246) | (5,555) | |||||||
CAPEX | (265) | (747) | |||||||
Cash from investing activities | (10,207) | (3,512) | |||||||
Cash from financing activities | 9,641 | (627) | |||||||
FCF | 51,974 | (4,060) | |||||||
Balance | |||||||||
Cash | 5,147 | 8,959 | |||||||
Long term investments | 3,084 | 3,084 | |||||||
Excess cash | 4,982 | 9,751 | |||||||
Stockholders' equity | (28,273) | (23,494) | |||||||
Invested Capital | 87,992 | 72,037 | |||||||
ROIC | 66.24% | ||||||||
ROCE | 88.76% | ||||||||
EV | |||||||||
Common stock shares outstanding | 8,279 | 7,907 | |||||||
Price | 41.10 -9.67% | 45.50 53.98% | |||||||
Market cap | 340,265 -5.42% | 359,759 65.83% | |||||||
EV | 346,041 | 349,247 | |||||||
EBITDA | 56,680 | (7,490) | |||||||
EV/EBITDA | 6.11 | ||||||||
Interest | 476 | 285 | |||||||
Interest/NOPBT | 0.90% |